2. Albritton, W. L. et al. 1984. Plasmid-mcdiated tetracycline resis- tance in Haemophilus ducreyi. Antimi- crob. Agents Chemother., in press.

3. Bilgeri, Y. R. et al. 1982. Antimicro- bial susceptibility of 103 strains of Haemophilus ducreyi isolated in Jo- hannesburg. Antimicrob. Agents Chemother. 22:686-688.

4. Brunton, J. L. el al. 1979. Plasmid- mediated ampicillin resistance in tlae- mophilus ducreyi. Antimicrob. Agents Chemother. 15:294-299.

5. Fast, M. V. et al. 1983. Antimicro- bial therapy of chancroid: an evalua- tion of five regimens correlated with in vitro sensitivity. Sex. Transm. Dis. 10:1-6.

6. Fast, M. V. el al. 1982. Treatment of chancroid by clavulanic acid with amoxicllin in patients with B-lacta- mase-positive Haemophilus ducreyi in- fection. Lancet 2:509-511.

7. Fast, M. V. et al. 19~3. A compar- ison of sulfamethoxazole and trimetho- prim-sulfamethoxazole. Brit. J. Verier. Dis. 59:320-324.

8. Hammond, G. W. et al. 1978. Deter- mination of the heroin requirement of Haeraophil,ts ducreyi: evaluation of the porphyrin test and media used in the satellite growth test. J. Clin. Micro- biol. 7:243-246.

9. Hammond, G. W. et al. 1978. Com- parison of specimen collection and lab- oratory techniques for isolation of Haemophilus ducreyi. J. Clin. Micro- biol. 7:39-43.

10. Hammond, G. W. et al. 1978. Anti- microbial susceptibility of Haemo- philus ducreyi. 1978. Antimicrob. Agents Chemother. 13:608-612.

1 I. Hammond, G. W. et al. 1980. Epi- demiologic, clinical, laboratory, and therapeutic features of an urban out- break of chancroid in North America. Rev. Infect. Dis. 2:867-879.

12. Handsfield, H. H. et al. 1981. Mo- lecular epidemiology of Haemophilus ducreyi infections. Ann. Intern. Med. 95:315-318.

13. Hannah, P., and J. R. Greenwood. 1982. Isolation and rapid identification of Haemophilus ducreyi. 16:861-864.

14. Kinghorn, G. R., S. Hafiz, and M. G. McEntegart. 1982. Pathogenic microbial flora of genital ulcer in Sheffield with particular reference to herpes simplex and Haemophilus ducreyi. Brit. J. Vener. Dis. 58: 377-380.

15. Nsanze, ti. et al. 1981. Genital ulcers in Kenya: a clinical and laboratory study. Brit. J. Vener. Dis. 59: 378-381.

16. Nsanze, H. et al. 1983. Comparison of media for the primary isolation of

Haemophilus ducreyi. Sex. Transm. Dis., in press.

17. Piummer, F. A. et al. 1983. Epide- miology of chancroid and Haemophih¢s ducreyi in Kenya. Lancet 2:1293- 1295.

18. Plummet, F. A. et al. 1983. Antimi- crobial therapy of chancroid: effective- ness of erythromycin. J. Infect. Dis. 148:726-731.

19. Plummer, F. A. et al. 1983. Short- course and single-dose antimicrobial therapy of chancroid in Kenya: reports of studies with rifampin combined with trimethoprim and rifampin alone. Rev. Infect. Dis. 5:$566-571.

20. Hummer, F. A. et al. 1983. Single dose therapy of chancroid with tri- methoprim-sulfamethoxazole. N. Engl. J. Med. 309:67-71.

21. Ronald, A. R., and W. L. Albritton. Chancroid and Haemophilus ducreyi. hi K. K. Holmes, P-A. Mardh, P. F. Sparling, and P. J. Wiesner (eds.), Sexually transmitted diseases. McGraw-Hill, New York, in press.

22. Sottnek, F. O. et al. 1980. Isolation and identification of Haemophilus du- creyi in a clinical study. J. Clin. Mi- crobiol. 12:170-174.

23. Teague, O., and O. Deibert. 1920. The value of cultural method in the diagnosis of chancroid. J. Urol. 4: 543 -550.

In Memoriam

J o h n L a w r e n c e - - - F r i e n d and I n n o v a t o r

The editors of the Clinical Microbi- ology Newsletter were saddened re- cently when we were informed of the untimely death of our friend and col- league John Lawrence o f Elsevier. John had a central role in this publica- tion: it is largely due to John's efforts that the Clinical Microbiology News- letter was initiated. Approximately six years ago, John had joined the staff of G. K. Hall, where he was to develop a Medical Book Division. During his initial year with G. K. Hall, John vis-

i t e d many potential authors, including myself and Jo Morello, trying to de- velop new ideas and new publications. He was committed to innovation and committed to the field of microbi- ology. In our discussions, John asked if a newsletter might be useful in the field of Clinical Microbiology. While there was some potential, no clear

74

I | 1 1 | 1

0196-4399:84/$0.00 + 02.00

concept of the newsletter yet existed. John challenged Jo and me to develop such a publication. We were suffi- ciently intrigued as to commit our- selves to its development. Somewhat later, Donna Blazevic also agreed to accept the challenge. The three o f us, with John's encouragement and sup- port, developed and refined the con- cept of this newsletter. We introduced the Newsletter in January 1979, as a semimonthly publication, and have held to this schedule since. During the Newsletter's first year, John left G. K. Hall to assume a position with increased responsibility at Elsevier Sci- ence Publishing Company, Inc. We then were disappointed that John left, but understood how such a new chal- lenge could attract him.

At Elsevier, John ,continued his commitment to innovation and micro- biology. Approximately 18 months ago, we moved with the Newsletter to

© 1984 Elsevier Science Publishing Co., Inc.

Elsevier, and were reunited with John. John continued over the past two years to take special interest in this publica- tion, since it was the first, and among the most successful, publications among a growing number of newslet- ters.

Thus, the Clinical Microbiology Newsletter is and always will be in- debted to John Lawrence. Among John's accomplishments are the devel-

opment and support of the Clhffcal hn- munology Newsletter, the Infectious Diseases Newsletter, The Anthnicrobic Newsletter, and Diagnostic Microbi- ology and hlfectious Disease. John will always occupy a special place in our hearts and minds. Our thoughts and prayers are with John's family. It was indeed a pleasure to have known John. We will miss him.

Laurence M c C a r t h y

II

Clinical Microbiology Newsletter 6:10,1984